Ultragenyx Pharmaceutical Inc.
A biopharmaceutical company that develops and sells treatments for rare and ultra-rare genetic diseases, many of which had no approved therapy before. Its marketed medicines include CRYSVITA for a bone disorder called X-linked hypophosphatemia and MEPSEVII for a lysosomal storage disease. Founded in 2010 by pediatric geneticist Emil Kakkis, the company's name blends "ultra" (for ultra-rare diseases) with "genyx" (for genetics), and it trades on the stock market under the ticker symbol RARE.
Granted 494.9K · Sold 340.3K
Granted 225.5K · Sold 73.3K
Granted 124.6K · Sold 4.0K
Granted 124.6K · Sold 39.3K
Granted 134.8K · Sold 43.7K
Granted 102.2K · Sold 18.8K
Granted 156.2K · Sold 50.5K
Granted 137.7K · Sold 74.6K
Granted 65.6K · Sold 10.3K
Granted 34.0K · Sold 12.8K
Granted 21.7K · Sold 13.7K
Granted 26.0K
Granted 26.0K
Granted 26.0K
Granted 33.5K · Sold 12.2K
Granted 31.1K
Granted 26.0K · Sold 5.7K
Granted 26.0K · Sold 8.8K
Granted 3.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kakkis Emil DPresident & CEO, Director · 27 transactions | — | 4.85M | 494.9K | — | 340.3K |
| Kassberg Thomas RichardCBO & EVP · 20 transactions | +148.3% | 265.2Kas of Mar 2025 | 225.5K | — | 73.3K |
| Huang Dennis KarlSee Remarks · 16 transactions | +265% | 147.8K | 124.6K | — | 4.0K |
| Pinion John RichardSee Remarks · 19 transactions | +165.6% | 133.1K | 124.6K | — | 39.3K |
| Harris ErikEVP & Chief Commercial Officer · 18 transactions | +367.4% | 118.4K | 134.8K | — | 43.7K |
| Crombez EricEVP and Chief Medical Officer · 14 transactions | — | 111.2K | 102.2K | — | 18.8K |
| Horn HowardChief Financial Officer · 17 transactions | — | 105.7K | 156.2K | — | 50.5K |
| Parschauer Karah HerdmanEVP and Chief Legal Officer · 26 transactions | +229.5% | 94.5K | 137.7K | — | 74.6K |
| Huizenga Theodore AlanSVP, Chief Accounting Officer · 37 transactions | +358.5% | 68.9K | 65.6K | — | 10.3K |
| Dier MardiCFO & Executive Vice President · 8 transactions | +46.6% | 66.7Kas of Oct 2022 | 34.0K | — | 12.8K |
| Bedrosian Camille LEVP and Chief Medical Officer · 10 transactions | +20.5% | 46.7Kas of Mar 2023 | 21.7K | — | 13.7K |
| Narachi MichaelDirector · 5 transactions | +180% | 40.4K | 26.0K | — | — |
| Welch Daniel GDirector · 5 transactions | +180% | 40.4K | 26.0K | — | — |
| Dunsire DeborahDirector · 5 transactions | +206.8% | 38.6K | 26.0K | — | — |
| Fust Matthew KDirector · 10 transactions | +114.7% | 33.7K | 33.5K | — | 12.2K |
| Ray AmritDirector · 6 transactions | — | 31.1K | 31.1K | — | — |
| Suliman ShehnaazDirector · 6 transactions | +263.2% | 28.0K | 26.0K | — | 5.7K |
| Sanders Corazon (Corsee) D.Director · 11 transactions | +441.6% | 21.1K | 26.0K | — | 8.8K |
| Ekman LarsDirector · 1 transaction | +22.8% | 17.7Kas of Jun 2022 | 3.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -708.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.